Indication:
Biliary Cancer
Location:
Texas Oncology-San Antonio Downtown
Phase:
II
Title:
An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View
Indication:
Biliary Cancer
Location:
Texas Oncology-San Antonio Stone Oak
Phase:
II
Title:
An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View
Indication:
Biliary Cancer
Location:
Texas Oncology-San Antonio Northeast
Phase:
II
Title:
An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View
Indication:
Biliary Cancer
Location:
Texas Oncology-San Antonio Medical Center
Phase:
II
Title:
An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View
Indication:
Biliary Cancer
Location:
Texas Oncology-San Antonio Downtown
Phase:
II
Title:
A Phase 2, Open-Label, Single Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects with Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Translocations Who Failed Previous Therapy (INCB 54828-202) View
Indication:
Biliary Cancer
Location:
Texas Oncology-San Antonio Stone Oak
Phase:
II
Title:
A Phase 2, Open-Label, Single Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects with Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Translocations Who Failed Previous Therapy (INCB 54828-202) View
Indication:
Biliary Cancer
Location:
Texas Oncology-San Antonio Northeast
Phase:
II
Title:
A Phase 2, Open-Label, Single Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects with Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Translocations Who Failed Previous Therapy (INCB 54828-202) View
Indication:
Biliary Cancer
Location:
Texas Oncology-San Antonio Northeast
Phase:
II
Title:
A Phase 2, Open-Label, Single Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects with Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Translocations Who Failed Previous Therapy (INCB 54828-202) View
Indication:
Biliary Cancer
Location:
Texas Oncology-San Antonio Medical Center
Phase:
II
Title:
A Phase 2, Open-Label, Single Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects with Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Translocations Who Failed Previous Therapy (INCB 54828-202) View
Indication:
Biliary Cancer
Location:
Texas Oncology-San Antonio Medical Center
Phase:
II
Title:
A Phase 2, Open-Label, Single Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects with Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Translocations Who Failed Previous Therapy (INCB 54828-202) View
Indication:
Bladder Cancer
Location:
Texas Oncology-San Antonio Downtown
Phase:
II
Title:
A Phase 2, Open-label, Single Agent, Multi-Center Study to Evaluate the Efficacy and Safety of a Pan-FGFR Tyrosine Kinase Inhibitor INCB054828 in Patients with Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGF/FGFR Alterations (INCB 54828-201) View
Indication:
Bladder Cancer
Location:
Texas Oncology-San Antonio Stone Oak
Phase:
II
Title:
A Phase 2, Open-label, Single Agent, Multi-Center Study to Evaluate the Efficacy and Safety of a Pan-FGFR Tyrosine Kinase Inhibitor INCB054828 in Patients with Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGF/FGFR Alterations (INCB 54828-201) View
Indication:
Bladder Cancer
Location:
Texas Oncology-San Antonio Northeast
Phase:
II
Title:
A Phase 2, Open-label, Single Agent, Multi-Center Study to Evaluate the Efficacy and Safety of a Pan-FGFR Tyrosine Kinase Inhibitor INCB054828 in Patients with Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGF/FGFR Alterations (INCB 54828-201) View
Indication:
Bladder Cancer
Location:
Texas Oncology-San Antonio Northeast
Phase:
II
Title:
A Phase 2, Open-label, Single Agent, Multi-Center Study to Evaluate the Efficacy and Safety of a Pan-FGFR Tyrosine Kinase Inhibitor INCB054828 in Patients with Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGF/FGFR Alterations (INCB 54828-201) View
Indication:
Bladder Cancer
Location:
Texas Oncology-San Antonio Medical Center
Phase:
II
Title:
A Phase 2, Open-label, Single Agent, Multi-Center Study to Evaluate the Efficacy and Safety of a Pan-FGFR Tyrosine Kinase Inhibitor INCB054828 in Patients with Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGF/FGFR Alterations (INCB 54828-201) View
Indication:
Bladder Cancer
Location:
Texas Oncology-San Antonio Medical Center
Phase:
II
Title:
A Phase 2, Open-label, Single Agent, Multi-Center Study to Evaluate the Efficacy and Safety of a Pan-FGFR Tyrosine Kinase Inhibitor INCB054828 in Patients with Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGF/FGFR Alterations (INCB 54828-201) View
Indication:
Breast Cancer
Location:
Texas Oncology-San Antonio Downtown
Phase:
II
Title:
(USO 13033/ Millennium X14021) A Phase II, Multicenter, Randomized, Parallel Group Study to Compare Alisertib in Combination with Paclitaxel vs. Paclitaxel Alone in Patients with Metastatic or Locally Recurrent Breast Cancer View
Indication:
Breast Cancer
Location:
Texas Oncology-San Antonio Stone Oak
Phase:
II
Title:
(USO 13033/ Millennium X14021) A Phase II, Multicenter, Randomized, Parallel Group Study to Compare Alisertib in Combination with Paclitaxel vs. Paclitaxel Alone in Patients with Metastatic or Locally Recurrent Breast Cancer View
Indication:
Breast Cancer
Location:
Texas Oncology-San Antonio Northeast
Phase:
II
Title:
(USO 13033/ Millennium X14021) A Phase II, Multicenter, Randomized, Parallel Group Study to Compare Alisertib in Combination with Paclitaxel vs. Paclitaxel Alone in Patients with Metastatic or Locally Recurrent Breast Cancer View
Indication:
Breast Cancer
Location:
Texas Oncology-San Antonio Downtown
Phase:
II
Title:
A Phase 1/2 Open-Label Study to Evaluate the Safety,
Pharmacokinetics, Pharmacodynamics and Efficacy of Seviteronel in Subjects with Advanced Breast Cancer.(INO-VT-464-CL-006) View
Indication:
Breast Cancer
Location:
Texas Oncology-San Antonio Stone Oak
Phase:
II
Title:
A Phase 1/2 Open-Label Study to Evaluate the Safety,
Pharmacokinetics, Pharmacodynamics and Efficacy of Seviteronel in Subjects with Advanced Breast Cancer.(INO-VT-464-CL-006) View
Indication:
Breast Cancer
Location:
Texas Oncology-San Antonio Northeast
Phase:
II
Title:
A Phase 1/2 Open-Label Study to Evaluate the Safety,
Pharmacokinetics, Pharmacodynamics and Efficacy of Seviteronel in Subjects with Advanced Breast Cancer.(INO-VT-464-CL-006) View
Indication:
Breast Cancer
Location:
Texas Oncology-San Antonio Medical Center
Phase:
II
Title:
A Phase 1/2 Open-Label Study to Evaluate the Safety,
Pharmacokinetics, Pharmacodynamics and Efficacy of Seviteronel in Subjects with Advanced Breast Cancer.(INO-VT-464-CL-006) View
Indication:
Breast Cancer
Location:
Texas Oncology-San Antonio Northeast
Phase:
II
Title:
Phase 2 Study of the Safety, Efficacy, and Pharmacokinetics of G1T28 in Patients with Metastatic Triple Negative Breast Cancer Receiving Gemcitabine and Carboplatin Chemotherapy (G1T28-04) View
Indication:
Breast Cancer
Location:
Texas Oncology-San Antonio Downtown
Phase:
II
Title:
Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib
vs. Placebo in Combination with Capecitabine and Trastuzumab in
Patients with Pretreated Unresectable Locally Advanced or Metastatic
HER2+ Breast Carcinoma
(HER2CLIMB) (ONT-380-206) View
Indication:
Breast Cancer
Location:
Texas Oncology-San Antonio Stone Oak
Phase:
II
Title:
Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib
vs. Placebo in Combination with Capecitabine and Trastuzumab in
Patients with Pretreated Unresectable Locally Advanced or Metastatic
HER2+ Breast Carcinoma
(HER2CLIMB) (ONT-380-206) View
Indication:
Breast Cancer
Location:
Texas Oncology-San Antonio Northeast
Phase:
II
Title:
Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib
vs. Placebo in Combination with Capecitabine and Trastuzumab in
Patients with Pretreated Unresectable Locally Advanced or Metastatic
HER2+ Breast Carcinoma
(HER2CLIMB) (ONT-380-206) View
Indication:
Breast Cancer
Location:
Texas Oncology-San Antonio Medical Center
Phase:
II
Title:
Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib
vs. Placebo in Combination with Capecitabine and Trastuzumab in
Patients with Pretreated Unresectable Locally Advanced or Metastatic
HER2+ Breast Carcinoma
(HER2CLIMB) (ONT-380-206) View
Indication:
Breast Cancer
Location:
Texas Oncology-San Antonio Downtown
Phase:
II
Title:
CLEE011G2301: A phase III, multicenter, randomized, double-blind, placebo-controlled study to evaluate efficacy and safety of ribociclib with endocrine therapy as an adjuvant treatment in patients with hormone receptor-positive, HER2-negative, high risk early breast cancer View
Indication:
Breast Cancer
Location:
Texas Oncology-San Antonio Stone Oak
Phase:
II
Title:
CLEE011G2301: A phase III, multicenter, randomized, double-blind, placebo-controlled study to evaluate efficacy and safety of ribociclib with endocrine therapy as an adjuvant treatment in patients with hormone receptor-positive, HER2-negative, high risk early breast cancer View
Indication:
Breast Cancer
Location:
Texas Oncology-San Antonio Northeast
Phase:
II
Title:
CLEE011G2301: A phase III, multicenter, randomized, double-blind, placebo-controlled study to evaluate efficacy and safety of ribociclib with endocrine therapy as an adjuvant treatment in patients with hormone receptor-positive, HER2-negative, high risk early breast cancer View
Indication:
Cervical Cancer
Location:
Texas Oncology-San Antonio Downtown
Phase:
II
Title:
An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View
Indication:
Cervical Cancer
Location:
Texas Oncology-San Antonio Stone Oak
Phase:
II
Title:
An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View
Indication:
Cervical Cancer
Location:
Texas Oncology-San Antonio Northeast
Phase:
II
Title:
An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View
Indication:
Cervical Cancer
Location:
Texas Oncology-San Antonio Medical Center
Phase:
II
Title:
An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View
Indication:
Endometrial Cancer
Location:
Texas Oncology-San Antonio Downtown
Phase:
II
Title:
An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View
Indication:
Endometrial Cancer
Location:
Texas Oncology-San Antonio Stone Oak
Phase:
II
Title:
An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View
Indication:
Endometrial Cancer
Location:
Texas Oncology-San Antonio Northeast
Phase:
II
Title:
An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View
Indication:
Endometrial Cancer
Location:
Texas Oncology-San Antonio Medical Center
Phase:
II
Title:
An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View
Indication:
Gastric Cancer
Location:
Texas Oncology-San Antonio Downtown
Phase:
II
Title:
An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View
Indication:
Gastric Cancer
Location:
Texas Oncology-San Antonio Stone Oak
Phase:
II
Title:
An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View
Indication:
Gastric Cancer
Location:
Texas Oncology-San Antonio Northeast
Phase:
II
Title:
An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View
Indication:
Gastric Cancer
Location:
Texas Oncology-San Antonio Medical Center
Phase:
II
Title:
An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View
Indication:
Head and Neck Cancer
Location:
Texas Oncology-San Antonio Downtown
Phase:
II
Title:
An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View
Indication:
Head and Neck Cancer
Location:
Texas Oncology-San Antonio Stone Oak
Phase:
II
Title:
An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View
Indication:
Head and Neck Cancer
Location:
Texas Oncology-San Antonio Northeast
Phase:
II
Title:
An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View
Indication:
Head and Neck Cancer
Location:
Texas Oncology-San Antonio Medical Center
Phase:
II
Title:
An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View
Indication:
Leukemia
Location:
Texas Oncology-San Antonio Downtown
Phase:
II
Title:
(UTX-TGR-204) A Multi-Center, Open-Label, Compassionate Use Extension Study of Ublituximab (TG-1101) in Combination with TGR-1202 for Patients Previously Enrolled in Protocol UTX-TGR-304 View
Indication:
Leukemia
Location:
Texas Oncology-San Antonio Stone Oak
Phase:
II
Title:
(UTX-TGR-204) A Multi-Center, Open-Label, Compassionate Use Extension Study of Ublituximab (TG-1101) in Combination with TGR-1202 for Patients Previously Enrolled in Protocol UTX-TGR-304 View
Indication:
Leukemia
Location:
Texas Oncology-San Antonio Northeast
Phase:
II
Title:
(UTX-TGR-204) A Multi-Center, Open-Label, Compassionate Use Extension Study of Ublituximab (TG-1101) in Combination with TGR-1202 for Patients Previously Enrolled in Protocol UTX-TGR-304 View
Indication:
Leukemia
Location:
Texas Oncology-San Antonio Medical Center
Phase:
II
Title:
(UTX-TGR-204) A Multi-Center, Open-Label, Compassionate Use Extension Study of Ublituximab (TG-1101) in Combination with TGR-1202 for Patients Previously Enrolled in Protocol UTX-TGR-304 View
Indication:
Lung Cancer
Location:
Texas Oncology-San Antonio Downtown
Phase:
II
Title:
CA209370: A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance after Induction Chemotherapy or as First-line Treatment Alone or in Combination with Standard of Care Therapies View
Indication:
Lung Cancer
Location:
Texas Oncology-San Antonio Stone Oak
Phase:
II
Title:
CA209370: A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance after Induction Chemotherapy or as First-line Treatment Alone or in Combination with Standard of Care Therapies View
Indication:
Lung Cancer
Location:
Texas Oncology-San Antonio Northeast
Phase:
II
Title:
CA209370: A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance after Induction Chemotherapy or as First-line Treatment Alone or in Combination with Standard of Care Therapies View
Indication:
Lung Cancer
Location:
Texas Oncology-San Antonio Downtown
Phase:
II
Title:
A Phase II single-arm trial to investigate tepotinib in
advanced (Stage IIIB/IV) non-small cell lung cancer
with MET exon 14 (METex14) skipping alterations
(VISION) View
Indication:
Lung Cancer
Location:
Texas Oncology-San Antonio Stone Oak
Phase:
II
Title:
A Phase II single-arm trial to investigate tepotinib in
advanced (Stage IIIB/IV) non-small cell lung cancer
with MET exon 14 (METex14) skipping alterations
(VISION) View
Indication:
Lung Cancer
Location:
Texas Oncology-San Antonio Northeast
Phase:
II
Title:
A Phase II single-arm trial to investigate tepotinib in
advanced (Stage IIIB/IV) non-small cell lung cancer
with MET exon 14 (METex14) skipping alterations
(VISION) View
Indication:
Lymphomas
Location:
Texas Oncology-San Antonio Downtown
Phase:
II
Title:
SGN35-015:A phase 2 open-label study of brentuximab vedotin in front-line therapy of Hodgkin lymphoma (HL) in adults age 60 and above View
Indication:
Lymphomas
Location:
Texas Oncology-San Antonio Northeast
Phase:
II
Title:
SGN35-015:A phase 2 open-label study of brentuximab vedotin in front-line therapy of Hodgkin lymphoma (HL) in adults age 60 and above View
Indication:
Lymphomas
Location:
Texas Oncology-San Antonio Medical Center
Phase:
II
Title:
SGN35-015:A phase 2 open-label study of brentuximab vedotin in front-line therapy of Hodgkin lymphoma (HL) in adults age 60 and above View
Indication:
Lymphomas
Location:
Texas Oncology-San Antonio Downtown
Phase:
II
Title:
A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR-1202 with or without Bendamustine and TGR-1202 alone in Patients with Previously Treated Non-Hodgkin’s Lymphoma (UTX-TGR-205) View
Indication:
Lymphomas
Location:
Texas Oncology-San Antonio Stone Oak
Phase:
II
Title:
A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR-1202 with or without Bendamustine and TGR-1202 alone in Patients with Previously Treated Non-Hodgkin’s Lymphoma (UTX-TGR-205) View
Indication:
Lymphomas
Location:
Texas Oncology-San Antonio Northeast
Phase:
II
Title:
A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR-1202 with or without Bendamustine and TGR-1202 alone in Patients with Previously Treated Non-Hodgkin’s Lymphoma (UTX-TGR-205) View
Indication:
Lymphomas
Location:
Texas Oncology-San Antonio Medical Center
Phase:
II
Title:
A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR-1202 with or without Bendamustine and TGR-1202 alone in Patients with Previously Treated Non-Hodgkin’s Lymphoma (UTX-TGR-205) View
Indication:
Mesothelioma
Location:
Texas Oncology-San Antonio Downtown
Phase:
II
Title:
An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View
Indication:
Mesothelioma
Location:
Texas Oncology-San Antonio Stone Oak
Phase:
II
Title:
An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View
Indication:
Mesothelioma
Location:
Texas Oncology-San Antonio Northeast
Phase:
II
Title:
An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View
Indication:
Mesothelioma
Location:
Texas Oncology-San Antonio Medical Center
Phase:
II
Title:
An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View
Indication:
Neuroendocrine Tumors
Location:
Texas Oncology-San Antonio Downtown
Phase:
II
Title:
An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View
Indication:
Neuroendocrine Tumors
Location:
Texas Oncology-San Antonio Stone Oak
Phase:
II
Title:
An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View
Indication:
Neuroendocrine Tumors
Location:
Texas Oncology-San Antonio Northeast
Phase:
II
Title:
An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View
Indication:
Neuroendocrine Tumors
Location:
Texas Oncology-San Antonio Medical Center
Phase:
II
Title:
An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View
Indication:
Penile Cancer
Location:
Texas Oncology-San Antonio Downtown
Phase:
II
Title:
An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View
Indication:
Penile Cancer
Location:
Texas Oncology-San Antonio Stone Oak
Phase:
II
Title:
An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View
Indication:
Penile Cancer
Location:
Texas Oncology-San Antonio Northeast
Phase:
II
Title:
An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View
Indication:
Penile Cancer
Location:
Texas Oncology-San Antonio Medical Center
Phase:
II
Title:
An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View
Indication:
Prostate Cancer
Location:
Texas Oncology-San Antonio Downtown
Phase:
II
Title:
TRITON2: A Multicenter, Open-label Phase 2 Study of Rucaparib in
Patients with Metastatic Castration-resistant Prostate Cancer Associated with Homologous Recombination Deficiency - CO-338-052 View
Indication:
Prostate Cancer
Location:
Texas Oncology-San Antonio Stone Oak
Phase:
II
Title:
TRITON2: A Multicenter, Open-label Phase 2 Study of Rucaparib in
Patients with Metastatic Castration-resistant Prostate Cancer Associated with Homologous Recombination Deficiency - CO-338-052 View
Indication:
Prostate Cancer
Location:
Texas Oncology-San Antonio Northeast
Phase:
II
Title:
TRITON2: A Multicenter, Open-label Phase 2 Study of Rucaparib in
Patients with Metastatic Castration-resistant Prostate Cancer Associated with Homologous Recombination Deficiency - CO-338-052 View
Indication:
Prostate Cancer
Location:
Texas Oncology-San Antonio Medical Center
Phase:
II
Title:
TRITON2: A Multicenter, Open-label Phase 2 Study of Rucaparib in
Patients with Metastatic Castration-resistant Prostate Cancer Associated with Homologous Recombination Deficiency - CO-338-052 View
Indication:
Rectal Cancer
Location:
Texas Oncology-San Antonio Downtown
Phase:
II
Title:
An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View
Indication:
Rectal Cancer
Location:
Texas Oncology-San Antonio Stone Oak
Phase:
II
Title:
An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View
Indication:
Rectal Cancer
Location:
Texas Oncology-San Antonio Northeast
Phase:
II
Title:
An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View
Indication:
Rectal Cancer
Location:
Texas Oncology-San Antonio Medical Center
Phase:
II
Title:
An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View
Indication:
Solid Tumors
Location:
Texas Oncology-San Antonio Downtown
Phase:
II
Title:
An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View
Indication:
Solid Tumors
Location:
Texas Oncology-San Antonio Stone Oak
Phase:
II
Title:
An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View
Indication:
Solid Tumors
Location:
Texas Oncology-San Antonio Northeast
Phase:
II
Title:
An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View
Indication:
Solid Tumors
Location:
Texas Oncology-San Antonio Medical Center
Phase:
II
Title:
An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View
Indication:
Testicular Cancer
Location:
Texas Oncology-San Antonio Downtown
Phase:
II
Title:
An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View
Indication:
Testicular Cancer
Location:
Texas Oncology-San Antonio Stone Oak
Phase:
II
Title:
An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View
Indication:
Testicular Cancer
Location:
Texas Oncology-San Antonio Northeast
Phase:
II
Title:
An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View
Indication:
Testicular Cancer
Location:
Texas Oncology-San Antonio Medical Center
Phase:
II
Title:
An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View
Indication:
Thymomas
Location:
Texas Oncology-San Antonio Downtown
Phase:
II
Title:
An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View
Indication:
Thymomas
Location:
Texas Oncology-San Antonio Stone Oak
Phase:
II
Title:
An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View
Indication:
Thymomas
Location:
Texas Oncology-San Antonio Northeast
Phase:
II
Title:
An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View
Indication:
Thymomas
Location:
Texas Oncology-San Antonio Medical Center
Phase:
II
Title:
An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View
Indication:
Thyroid Cancer
Location:
Texas Oncology-San Antonio Downtown
Phase:
II
Title:
An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View
Indication:
Thyroid Cancer
Location:
Texas Oncology-San Antonio Stone Oak
Phase:
II
Title:
An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View
Indication:
Thyroid Cancer
Location:
Texas Oncology-San Antonio Northeast
Phase:
II
Title:
An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View
Indication:
Thyroid Cancer
Location:
Texas Oncology-San Antonio Medical Center
Phase:
II
Title:
An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View
Indication:
Urothelial Cancer
Location:
Texas Oncology-San Antonio Downtown
Phase:
II
Title:
A Phase 2, Open-label, Single Agent, Multi-Center Study to Evaluate the Efficacy and Safety of a Pan-FGFR Tyrosine Kinase Inhibitor INCB054828 in Patients with Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGF/FGFR Alterations (INCB 54828-201) View
Indication:
Urothelial Cancer
Location:
Texas Oncology-San Antonio Stone Oak
Phase:
II
Title:
A Phase 2, Open-label, Single Agent, Multi-Center Study to Evaluate the Efficacy and Safety of a Pan-FGFR Tyrosine Kinase Inhibitor INCB054828 in Patients with Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGF/FGFR Alterations (INCB 54828-201) View
Indication:
Urothelial Cancer
Location:
Texas Oncology-San Antonio Northeast
Phase:
II
Title:
A Phase 2, Open-label, Single Agent, Multi-Center Study to Evaluate the Efficacy and Safety of a Pan-FGFR Tyrosine Kinase Inhibitor INCB054828 in Patients with Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGF/FGFR Alterations (INCB 54828-201) View
Indication:
Urothelial Cancer
Location:
Texas Oncology-San Antonio Northeast
Phase:
II
Title:
A Phase 2, Open-label, Single Agent, Multi-Center Study to Evaluate the Efficacy and Safety of a Pan-FGFR Tyrosine Kinase Inhibitor INCB054828 in Patients with Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGF/FGFR Alterations (INCB 54828-201) View
Indication:
Urothelial Cancer
Location:
Texas Oncology-San Antonio Medical Center
Phase:
II
Title:
A Phase 2, Open-label, Single Agent, Multi-Center Study to Evaluate the Efficacy and Safety of a Pan-FGFR Tyrosine Kinase Inhibitor INCB054828 in Patients with Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGF/FGFR Alterations (INCB 54828-201) View
Indication:
Urothelial Cancer
Location:
Texas Oncology-San Antonio Medical Center
Phase:
II
Title:
A Phase 2, Open-label, Single Agent, Multi-Center Study to Evaluate the Efficacy and Safety of a Pan-FGFR Tyrosine Kinase Inhibitor INCB054828 in Patients with Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGF/FGFR Alterations (INCB 54828-201) View
Indication:
Uterine Cancer
Location:
Texas Oncology-San Antonio Downtown
Phase:
II
Title:
An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View
Indication:
Uterine Cancer
Location:
Texas Oncology-San Antonio Stone Oak
Phase:
II
Title:
An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View
Indication:
Uterine Cancer
Location:
Texas Oncology-San Antonio Northeast
Phase:
II
Title:
An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View
Indication:
Uterine Cancer
Location:
Texas Oncology-San Antonio Medical Center
Phase:
II
Title:
An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View
Indication:
Vaginal Cancer
Location:
Texas Oncology-San Antonio Downtown
Phase:
II
Title:
An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View
Indication:
Vaginal Cancer
Location:
Texas Oncology-San Antonio Stone Oak
Phase:
II
Title:
An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View
Indication:
Vaginal Cancer
Location:
Texas Oncology-San Antonio Northeast
Phase:
II
Title:
An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View
Indication:
Vaginal Cancer
Location:
Texas Oncology-San Antonio Medical Center
Phase:
II
Title:
An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View